Personalized treatment of extensive stage small cell lung cancer: A case report and literature review

A 50-year-old female patient presented with post-exercise dyspnea in September 2016, and was subsequently diagnosed with SCLC with multiple brain and spinal metastases. The first-line treatment was etoposide combined with cisplatin and synchronously performed radiotherapy for the brain and spinal co...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2022-08, Vol.12
Main Authors: Wang, Huaiyu, Wang, Xuning, Jiang, Suxin, Zhu, Jingna, Liu, Jie, Zhou, Chuanhong, Zhu, Yanjun, Han, Yong
Format: Article
Language:English
Subjects:
anlotinib
bTMB
durvalumab
extensive-stage small cell lung cancer
long survival
NGS
Oncology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 50-year-old female patient presented with post-exercise dyspnea in September 2016, and was subsequently diagnosed with SCLC with multiple brain and spinal metastases. The first-line treatment was etoposide combined with cisplatin and synchronously performed radiotherapy for the brain and spinal cord metastases. She was treated with anlotinib after disease progression in December 2018 and continued to have clinical benefit for nearly 25 months. Unexpectedly, the patient can still benefit from further combination treatment with durvalumab after another disease progression in February 2021. Thus, it may be a potential option to use anlotinib along with immunotherapy after the anlotinib resistance in SCLC, but more clinical data are still needed to confirm it. Moreover, ctDNA dynamic monitoring was performed and reflected the outcome of the process of treatment.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.956372